Karl C K Kuban1, Robert M Joseph2, Thomas M O'Shea3, Timothy Heeren4, Raina N Fichorova5, Laurie Douglass6, Hernan Jara7, Jean A Frazier8, Deborah Hirtz9, Julie Vanier Rollins6, Nigel Paneth10. 1. Department of Pediatrics, Boston Medical Center, Boston, MA. Electronic address: karl.kuban@bmc.org. 2. Department of Anatomy and Neuroanatomy, Boston University School of Medicine, Boston, MA. 3. Department of Pediatrics, Division of Neonatal-Perinatal Medicine, University of North Carolina, Chapel Hill, NC. 4. Department of Biostatistics, Boston University School of Public Health, Boston, MA. 5. Laboratory of Genital Tract Biology, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 6. Department of Pediatrics, Boston Medical Center, Boston, MA. 7. Department of Radiology, Boston University School of Medicine, Boston, MA. 8. Department of Psychiatry, University of Massachusetts Medical School/ University of Massachusetts Memorial Health Care, Worcester, MA. 9. National Institute of Neurological Disorders and Stroke, Bethesda, MD. 10. Department of Epidemiology and Biostatistics and Pediatrics, Michigan State University, East Lansing, MI.
Abstract
OBJECTIVES: To evaluate whether in children born extremely preterm, indicators of sustained systemic inflammation in the first month of life are associated with cognitive impairment at school age. STUDY DESIGN: A total of 873 of 966 eligible children previously enrolled in the multicenter Extremely Low Gestational Age Newborn Study from 2002 to 2004 were evaluated at age 10 years. We analyzed the relationship between elevated blood concentrations of inflammation-associated proteins in the first 2 weeks ("early elevations"; n = 812) and the third and fourth week ("late elevations"; n = 532) of life with neurocognition. RESULTS: Early elevations of C-reactive protein, tumor necrosis factor-α, interleukin (IL)-8, intercellular adhesion molecule (ICAM)-1, and erythropoietin were associated with IQ values >2 SD below the expected mean (ORs: 2.0-2.3) and with moderate to severe cognitive impairment on a composite measure of IQ and executive function (ORs: 2.1-3.6). Additionally, severe cognitive impairment was associated with late protein elevations of C-reactive protein (OR: 4.0; 95% CI 1.5, 10), IL-8 (OR: 5.0; 1.9, 13), ICAM-1 (OR: 6.5; 2.6, 16), vascular endothelial growth factor-receptor 2 (OR: 3.2; 1.2, 8.3), and thyroid-stimulating hormone (OR: 3.1; 1.3, 7.3). Moderate cognitive impairment was most strongly associated with elevations of IL-8, ICAM-1, and vascular endothelial growth factor-receptor 2. When 4 or more inflammatory proteins were elevated early, the risk of having an IQ <70 and having overall impaired cognitive ability was more than doubled (ORs: 2.1-2.4); the presence of 4 or more inflammatory protein elevated late was strongly linked to adverse cognitive outcomes (ORs: 2.9-4.8). CONCLUSIONS: Extremely preterm children who had sustained elevations of inflammation-related proteins in the first postnatal month are more likely than extremely preterm peers without such elevations to have cognitive impairment at 10 years.
OBJECTIVES: To evaluate whether in children born extremely preterm, indicators of sustained systemic inflammation in the first month of life are associated with cognitive impairment at school age. STUDY DESIGN: A total of 873 of 966 eligible children previously enrolled in the multicenter Extremely Low Gestational Age Newborn Study from 2002 to 2004 were evaluated at age 10 years. We analyzed the relationship between elevated blood concentrations of inflammation-associated proteins in the first 2 weeks ("early elevations"; n = 812) and the third and fourth week ("late elevations"; n = 532) of life with neurocognition. RESULTS: Early elevations of C-reactive protein, tumor necrosis factor-α, interleukin (IL)-8, intercellular adhesion molecule (ICAM)-1, and erythropoietin were associated with IQ values >2 SD below the expected mean (ORs: 2.0-2.3) and with moderate to severe cognitive impairment on a composite measure of IQ and executive function (ORs: 2.1-3.6). Additionally, severe cognitive impairment was associated with late protein elevations of C-reactive protein (OR: 4.0; 95% CI 1.5, 10), IL-8 (OR: 5.0; 1.9, 13), ICAM-1 (OR: 6.5; 2.6, 16), vascular endothelial growth factor-receptor 2 (OR: 3.2; 1.2, 8.3), and thyroid-stimulating hormone (OR: 3.1; 1.3, 7.3). Moderate cognitive impairment was most strongly associated with elevations of IL-8, ICAM-1, and vascular endothelial growth factor-receptor 2. When 4 or more inflammatory proteins were elevated early, the risk of having an IQ <70 and having overall impaired cognitive ability was more than doubled (ORs: 2.1-2.4); the presence of 4 or more inflammatory protein elevated late was strongly linked to adverse cognitive outcomes (ORs: 2.9-4.8). CONCLUSIONS: Extremely preterm children who had sustained elevations of inflammation-related proteins in the first postnatal month are more likely than extremely preterm peers without such elevations to have cognitive impairment at 10 years.
Authors: Adel Helmy; Maria-Grazia De Simoni; Mathew R Guilfoyle; Keri L H Carpenter; Peter J Hutchinson Journal: Prog Neurobiol Date: 2011-09-16 Impact factor: 11.685
Authors: Melissa D Cantley; David P Fairlie; P Mark Bartold; Victor Marino; Praveer K Gupta; David R Haynes Journal: Rheumatology (Oxford) Date: 2015-03-31 Impact factor: 7.580
Authors: María Carmen Collado; María Cernada; Josef Neu; Gaspar Pérez-Martínez; María Gormaz; Máximo Vento Journal: Pediatr Res Date: 2015-03-11 Impact factor: 3.756
Authors: T Michael O'Shea; Bhavesh Shah; Elizabeth N Allred; Raina N Fichorova; Karl C K Kuban; Olaf Dammann; Alan Leviton Journal: Brain Behav Immun Date: 2013-01-04 Impact factor: 7.217
Authors: Olaf Dammann; Wolfgang Bueter; Alan Leviton; Pierre Gressens; Christiane E L Dammann Journal: Neonatology Date: 2007-11-09 Impact factor: 4.035
Authors: Michael W Varner; Nicole E Marshall; Dwight J Rouse; Kathleen A Jablonski; Kenneth J Leveno; Uma M Reddy; Brian M Mercer; Jay D Iams; Ronald J Wapner; Yoram Sorokin; John M Thorp; Fergal D Malone; Marshall Carpenter; Mary J O'Sullivan; Alan M Peaceman; Gary D V Hankins; Donald J Dudley; Steve N Caritis Journal: Am J Perinatol Date: 2014-06-17 Impact factor: 1.862
Authors: Karl C K Kuban; T Michael O'Shea; Elizabeth N Allred; Nigel Paneth; Deborah Hirtz; Raina N Fichorova; Alan Leviton Journal: J Child Neurol Date: 2014-03-18 Impact factor: 1.987
Authors: Elizabeth N Allred; Olaf Dammann; Raina N Fichorova; Stephen R Hooper; Scott J Hunter; Robert M Joseph; Karl Kuban; Alan Leviton; Thomas Michael O'Shea; Megan N Scott Journal: J Neuroimmune Pharmacol Date: 2017-04-12 Impact factor: 4.147
Authors: Martha Scott Tomlinson; Kun Lu; Jill R Stewart; Carmen J Marsit; T Michael O'Shea; Rebecca C Fry Journal: Clin Microbiol Rev Date: 2019-05-01 Impact factor: 26.132
Authors: Marliese Dion Nist; Rita H Pickler; Tondi M Harrison; Deborah K Steward; Abigail B Shoben Journal: Early Hum Dev Date: 2020-05-22 Impact factor: 2.079
Authors: Alan Leviton; Robert M Joseph; Raina N Fichorova; Elizabeth N Allred; H Gerry Taylor; T Michael O'Shea; Olaf Dammann Journal: J Neuroimmune Pharmacol Date: 2018-09-06 Impact factor: 4.147
Authors: Lotte G van den Heuij; Mhoyra Fraser; Suzanne L Miller; Graham Jenkin; Euan M Wallace; Joanne O Davidson; Christopher A Lear; Rebecca Lim; Guido Wassink; Alistair J Gunn; Laura Bennet Journal: J Cereb Blood Flow Metab Date: 2017-09-12 Impact factor: 6.200
Authors: Naoise Mac Giollabhui; Elizabeth C Breen; Shannon K Murphy; Seth D Maxwell; Barbara A Cohn; Nickilou Y Krigbaum; Piera M Cirillo; Christian Perez; Lauren B Alloy; Deborah A G Drabick; Lauren M Ellman Journal: J Psychiatr Res Date: 2019-01-10 Impact factor: 4.791
Authors: Karl C K Kuban; Hernan Jara; T Michael O'Shea; Timothy Heeren; Robert M Joseph; Raina N Fichorova; Khalid Alshamrani; Adam Aakil; Forrest Beaulieu; Mitchell Horn; Laurie M Douglass; Jean A Frazier; Deborah Hirtz; Julie Vanier Rollins; David Cochran; Nigel Paneth Journal: J Pediatr Date: 2019-05-07 Impact factor: 4.406
Authors: Sudhir Sriram; Michael D Schreiber; Michael E Msall; Karl C K Kuban; Robert M Joseph; T Michael O' Shea; Elizabeth N Allred; Alan Leviton Journal: Pediatrics Date: 2018-05-17 Impact factor: 7.124